Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/daiichi-sankyo-co-ltd" target="_blank" data-smartkarma-citation="entities:3014:1" rel="noopener">Daiichi Sankyo (4568 JP)</a> has announced 9MFY26 results, with revenue increasing 12%, driven by 25% YoY growth in Enhertu product sales. Fx impacted negatively.</li>
<li>The company reiterated FY26 guidance. However, they tweaked key products revenue slightly. Indication and geography expansion of Enhertu and Datroway will be the key drivers.</li>
<li>The company plans to launch numerous indications across at least four ADCs by 2030, which should increase addressable patient population by nearly six times to ~700K from current ~120K.</li>
</ul>



Daiichi Sankyo (4568 JP) has announced 9MFY26 results, with revenue increasing 12%, driven by 25% YoY growth in Enhertu product sales. Fx impacted negatively.
The company reiterated FY26 guidance. However, they tweaked key products revenue slightly. Indication and geography expansion of Enhertu and Datroway will be the key drivers.
The company plans to launch numerous indications across at least four ADCs by 2030, which should increase addressable patient population by nearly six times to ~700K from current ~120K.


Daiichi Sankyo (4568 JP): Enhertu Drives 9MFY26 Result; FY Guidance Reiterated

<ul>
<li>
<a href="https://www.smartkarma.com/entities/takeda-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:11747:1" rel="noopener">Takeda Pharmaceutical (4502 JP)</a> has announced 9MFY26 result, with revenue declining 3% YoY to ¥3,411B, dragged by Vyvanse. Growth and launch products revenue grew 7%, with improving QoQ growth rate.</li>
<li>The company raised its full-year forecasts based on cost discipline and FX tailwind, while its revenue management guidance has been updated primarily due to the impact of Vyvanse generics.</li>
<li>Takeda has multiple late-stage programs with multibillion-dollar peak revenue potential. The company is poised to launch three drugs in the next 18 months, setting it on a new growth trajectory.</li>
</ul>



Takeda Pharmaceutical (4502 JP) has announced 9MFY26 result, with revenue declining 3% YoY to ¥3,411B, dragged by Vyvanse. Growth and launch products revenue grew 7%, with improving QoQ growth rate.
The company raised its full-year forecasts based on cost discipline and FX tailwind, while its revenue management guidance has been updated primarily due to the impact of Vyvanse generics.
Takeda has multiple late-stage programs with multibillion-dollar peak revenue potential. The company is poised to launch three drugs in the next 18 months, setting it on a new growth trajectory.


Takeda Pharmaceutical (4502 JP): Decent 9MFY26 Show; Guidance Revision Amid New Leg of Growth

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

Hisamitsu Pharmaceutical Co / Event-Driven

<ul>
<li>Bloomberg reported that an entity owned by the CEO is considering an MBO of <a href="https://www.smartkarma.com/entities/hisamitsu-pharmaceutical-co" target="_blank" data-smartkarma-citation="entities:17008:1" rel="noopener">Hisamitsu Pharmaceutical Co (4530 JP)</a> at a valuation of around JPY450 billion.</li>
<li>Assuming that the rumoured valuation refers to market cap based on outstanding shares, it suggests an offer around JPY6,000, a 15.4% premium to the last close.</li>
<li>Hisamitsu confirmed that it plans to announce an MBO today. An offer of JPY6,000 is attractive compared to precedent transactions and peer multiples.  </li>
</ul>


Bloomberg reported that an entity owned by the CEO is considering an MBO of Hisamitsu Pharmaceutical Co (4530 JP) at a valuation of around JPY450 billion.
Assuming that the rumoured valuation refers to market cap based on outstanding shares, it suggests an offer around JPY6,000, a 15.4% premium to the last close.
Hisamitsu confirmed that it plans to announce an MBO today. An offer of JPY6,000 is attractive compared to precedent transactions and peer multiples.  


Hisamitsu Pharma (4530 JP): An Imminent MBO at a Rumoured JPY450 Billion Valuation

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shionogi-co-ltd" target="_blank" data-smartkarma-citation="entities:19535:1" rel="noopener">Shionogi &amp; Co (4507 JP)</a> is acquiring rare neurodegenerative disease drug Radicava for $2.5B. The transaction is expected to be immediately accretive in FY27, adding ~$700M in annual global sales.</li>
<li>This acquisition will solidify Shionogi’s strategic focus in rare disease and immediately establish a strong rare disease commercial platform in the U.S. market.</li>
<li>Shionogi has received approval in Japan for inlicensed drug Zurzuvae for the indication of depression and depressive state.</li>
</ul>



Shionogi &amp; Co (4507 JP) is acquiring rare neurodegenerative disease drug Radicava for $2.5B. The transaction is expected to be immediately accretive in FY27, adding ~$700M in annual global sales.
This acquisition will solidify Shionogi’s strategic focus in rare disease and immediately establish a strong rare disease commercial platform in the U.S. market.
Shionogi has received approval in Japan for inlicensed drug Zurzuvae for the indication of depression and depressive state.


Shionogi (4507 JP): $2.5B ALS Drug Buyout and New Approval To Accelerate Portfolio Diversification

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mandom-corp" target="_blank" data-smartkarma-citation="entities:8353:1" rel="noopener">Mandom Corp (4917 JP)</a> has disclosed that it has received a non-binding letter of intent from a third-party candidate, with purchase prices exceeding the CVC JPY2,520 offer.</li>
<li>The <a href="https://www.nikkei.com/article/DGXZQOUB0996J0Z01C25A2000000/" target="_blank" rel="noopener">Nikkei</a> identifies the bidder as KKR and states that the offer is over JPY2,800, a 11.1% premium to the CVC offer. KKR want a Board-recommended offer.</li>
<li>CVC has extended the close of its offer to 5 January 2026, but will need to revise terms as its irrevocables (particularly Murakami and Hibiki) can switch to KKR.</li>
</ul>



Mandom Corp (4917 JP) has disclosed that it has received a non-binding letter of intent from a third-party candidate, with purchase prices exceeding the CVC JPY2,520 offer.
The Nikkei identifies the bidder as KKR and states that the offer is over JPY2,800, a 11.1% premium to the CVC offer. KKR want a Board-recommended offer.
CVC has extended the close of its offer to 5 January 2026, but will need to revise terms as its irrevocables (particularly Murakami and Hibiki) can switch to KKR.


Mandom (4917 JP): When You Thought It Was Done, KKR Emerges as a Competing Bidder

Japan

Otsuka Holdings Co Ltd is a pharmaceutical company. The Company manufactures, sells, imports and exports pharmaceuticals, clinical testing, and medical equipment for intractable diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Otsuka Holdings (4578 JP)

Daiichi Sankyo (4568 JP): Enhertu Drives 9MFY26 Result; FY Guidance Reiterated

Daiichi Sankyo reports 12% revenue growth in 9MFY26, driven by 25% growth Enhertu sales. The company reiterated FY26 guidance. However, they...

Tina Banerjee

Takeda Pharmaceutical (4502 JP): Decent 9MFY26 Show; Guidance Revision Amid New Leg of Growth

Takeda Pharmaceutical reports 9MFY26 result with revenue declining 3%. The company raised FY26 forecasts on cost discipline and FX tailwind....

Tina Banerjee

Hisamitsu Pharma (4530 JP): An Imminent MBO at a Rumoured JPY450 Billion Valuation

Hisamitsu confirmed that it plans to announce an MBO today. An offer at the rumoured JPY450bn valuation is attractive compared to precedent...

Arun George

Shionogi (4507 JP): $2.5B ALS Drug Buyout and New Approval To Accelerate Portfolio Diversification

Shionogi acquires rare neurodegenerative drug Radicava for $2.5B, which is expected to boost annual global sales by $700M. The company got...

Tina Banerjee

Mandom (4917 JP): When You Thought It Was Done, KKR Emerges as a Competing Bidder

CVC has extended the close of its offer to 5 January 2026, but will need to revise terms as its irrevocables (particularly Murakami and Hibiki) can...

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Daiichi Sankyo (4568 JP): Enhertu Drives 9MFY26 Result; FY Guidance Reiterated

​Daiichi Sankyo reports 12% revenue growth in 9MFY26, driven by 25% growth Enhertu sales. The company reiterated FY26 guidance. However, they...

Tina Banerjee

Takeda Pharmaceutical (4502 JP): Decent 9MFY26 Show; Guidance Revision Amid New Leg of Growth

​Takeda Pharmaceutical reports 9MFY26 result with revenue declining 3%. The company raised FY26 forecasts on cost discipline and FX tailwind....

Tina Banerjee

Hisamitsu Pharma (4530 JP): An Imminent MBO at a Rumoured JPY450 Billion Valuation

Hisamitsu confirmed that it plans to announce an MBO today. An offer at the rumoured JPY450bn valuation is attractive compared to precedent...

Arun George

Shionogi (4507 JP): $2.5B ALS Drug Buyout and New Approval To Accelerate Portfolio Diversification

​Shionogi acquires rare neurodegenerative drug Radicava for $2.5B, which is expected to boost annual global sales by $700M. The company got...

Tina Banerjee

Mandom (4917 JP): When You Thought It Was Done, KKR Emerges as a Competing Bidder

CVC has extended the close of its offer to 5 January 2026, but will need to revise terms as its irrevocables (particularly Murakami and Hibiki) can...

Arun George

Daiichi Sankyo reports 12% revenue growth in 9MFY26, driven by 25% growth Enhertu sales. The company reiterated FY26 guidance. However, they...

Takeda Pharmaceutical reports 9MFY26 result with revenue declining 3%. The company raised FY26 forecasts on cost discipline and FX tailwind....

Shionogi acquires rare neurodegenerative drug Radicava for $2.5B, which is expected to boost annual global sales by $700M. The company got...